Effects of Telbivudine Treatment on the Circulating CD4⁺ T-Cell Subpopulations in Chronic Hepatitis B Patients

Table 2

Telbivudine treatment influence on CD4⁺ T-cell subtype-specific cytokines expressions in PBMCs from HBV patients.

Time points (weeks)	IFN-γ (pg/mL)	IL-4 (pg/mL)	IL-17 (pg/mL)	IL-23 (pg/mL)	TGF-β (pg/mL)	IL-10 (pg/mL)
Baseline	7.459±1.206	3.612±0.370	16.480±1.983	10.030±1.454	23.170±2.891	23.970±2.571
12	11.720±2.566	8.090±1.469 **	12.800±1.485	6.990±0.864	23.440±2.593	14.030±1.885 **
24	19.380±3.170 **	9.100±1.892 **	8.440±1.216 ***	6.100±1.009 *	18.610±2.365	7.820±0.908 ***
36	17.790±2.580 **	7.540±1.575 *	7.980±0.995 ***	5.760±0.618 **	14.950±2.668 *	6.746±0.903 ***
52	23.350±2.139 ***	10.900±1.488 ***	7.140±0.796 ***	4.740±0.722 **	10.610±1.759 ***	8.890±0.973 ***
Healthy	26.240±3.066 ***	14.710±2.080 ***	5.980±0.605 ***	3.370±0.517 ***	8.830±0.931 ***	3.530±0.332^***, #

Data are shown as mean ± SEM. *𝑃<0.05, **𝑃<0.01, and ***𝑃<0.001 versus   the respective baseline; ^#𝑃<0.001 versus 52-week value.